605 related articles for article (PubMed ID: 31220333)
1. Band ligation versus no intervention for primary prevention of upper gastrointestinal bleeding in adults with cirrhosis and oesophageal varices.
Vadera S; Yong CWK; Gluud LL; Morgan MY
Cochrane Database Syst Rev; 2019 Jun; 6(6):CD012673. PubMed ID: 31220333
[TBL] [Abstract][Full Text] [Related]
2. Band ligation versus sham or no intervention for primary prophylaxis of oesophageal variceal bleeding in children and adolescents with chronic liver disease or portal vein thrombosis.
Cifuentes LI; Gattini D; Torres-Robles R; Gana JC
Cochrane Database Syst Rev; 2021 Jan; 1(1):CD011561. PubMed ID: 33522602
[TBL] [Abstract][Full Text] [Related]
3. Endoscopic injection of cyanoacrylate glue versus other endoscopic procedures for acute bleeding gastric varices in people with portal hypertension.
Ríos Castellanos E; Seron P; Gisbert JP; Bonfill Cosp X
Cochrane Database Syst Rev; 2015 May; 2015(5):CD010180. PubMed ID: 25966446
[TBL] [Abstract][Full Text] [Related]
4. Sclerotherapy versus sham or no intervention for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis.
Gattini D; Cifuentes LI; Torres-Robles R; Gana JC
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD011573. PubMed ID: 32133620
[TBL] [Abstract][Full Text] [Related]
5. Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults.
Gluud LL; Krag A
Cochrane Database Syst Rev; 2012 Aug; (8):CD004544. PubMed ID: 22895942
[TBL] [Abstract][Full Text] [Related]
6. Treatment for bleeding oesophageal varices in people with decompensated liver cirrhosis: a network meta-analysis.
Roberts D; Best LM; Freeman SC; Sutton AJ; Cooper NJ; Arunan S; Begum T; Williams NR; Walshaw D; Milne EJ; Tapp M; Csenar M; Pavlov CS; Davidson BR; Tsochatzis E; Gurusamy KS
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013155. PubMed ID: 33837526
[TBL] [Abstract][Full Text] [Related]
7. Band ligation versus sclerotherapy for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis.
Gana JC; Cifuentes LI; Gattini D; Torres-Robles R
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD011803. PubMed ID: 33164205
[TBL] [Abstract][Full Text] [Related]
8. Beta-blockers versus placebo or no intervention for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis.
Cifuentes LI; Gattini D; Torres-Robles R; Gana JC
Cochrane Database Syst Rev; 2021 Jan; 1(1):CD011973. PubMed ID: 33498095
[TBL] [Abstract][Full Text] [Related]
9. Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis.
Simonetti RG; Perricone G; Robbins HL; Battula NR; Weickert MO; Sutton R; Khan S
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD000553. PubMed ID: 33089892
[TBL] [Abstract][Full Text] [Related]
10. Granulocyte colony-stimulating factor with or without stem or progenitor cell or growth factors infusion for people with compensated or decompensated advanced chronic liver disease.
Colli A; Fraquelli M; Prati D; Casazza G
Cochrane Database Syst Rev; 2023 Jun; 6(6):CD013532. PubMed ID: 37278488
[TBL] [Abstract][Full Text] [Related]
11. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.
Gluud LL; Vilstrup H; Morgan MY
Cochrane Database Syst Rev; 2016 May; 2016(5):CD003044. PubMed ID: 27153247
[TBL] [Abstract][Full Text] [Related]
12. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.
Gluud LL; Vilstrup H; Morgan MY
Cochrane Database Syst Rev; 2016 Apr; 4():CD003044. PubMed ID: 27089005
[TBL] [Abstract][Full Text] [Related]
13. Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy.
Goh ET; Andersen ML; Morgan MY; Gluud LL
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD002798. PubMed ID: 28796283
[TBL] [Abstract][Full Text] [Related]
14. Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy.
Goh ET; Andersen ML; Morgan MY; Gluud LL
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD002798. PubMed ID: 28745801
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D supplementation for chronic liver diseases in adults.
Bjelakovic G; Nikolova D; Bjelakovic M; Gluud C
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011564. PubMed ID: 29099543
[TBL] [Abstract][Full Text] [Related]
16. Ursodeoxycholic acid for primary biliary cirrhosis.
Rudic JS; Poropat G; Krstic MN; Bjelakovic G; Gluud C
Cochrane Database Syst Rev; 2012 Dec; 12(12):CD000551. PubMed ID: 23235576
[TBL] [Abstract][Full Text] [Related]
17. Emergency sclerotherapy versus vasoactive drugs for bleeding oesophageal varices in cirrhotic patients.
D'Amico G; Pagliaro L; Pietrosi G; Tarantino I
Cochrane Database Syst Rev; 2010 Mar; 2010(3):CD002233. PubMed ID: 20238318
[TBL] [Abstract][Full Text] [Related]
18. Platelet count, spleen length, and platelet count-to-spleen length ratio for the diagnosis of oesophageal varices in people with chronic liver disease or portal vein thrombosis.
Colli A; Gana JC; Yap J; Adams-Webber T; Rashkovan N; Ling SC; Casazza G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD008759. PubMed ID: 28444987
[TBL] [Abstract][Full Text] [Related]
19. Terlipressin versus other vasoactive drugs for hepatorenal syndrome.
Israelsen M; Krag A; Allegretti AS; Jovani M; Goldin AH; Winter RW; Gluud LL
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011532. PubMed ID: 28953318
[TBL] [Abstract][Full Text] [Related]
20. Branched-chain amino acids for people with hepatic encephalopathy.
Gluud LL; Dam G; Les I; Marchesini G; Borre M; Aagaard NK; Vilstrup H
Cochrane Database Syst Rev; 2017 May; 5(5):CD001939. PubMed ID: 28518283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
